Onco-hematology Molecular Testing Market Development Supported by Increasing Cancer Awareness

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Onco-hematology Molecular Testing Market- (By Blood Cancer Type, (Chronic Myeloid Leukemia, (Polycythemia Vera, Essential, Thrombocythaemia, Myelofibrosis), Myeloproliferative Neoplasms, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia), By Technology (qPCR, dPCR, Next-Generation Sequencing, Others), By Blood Cancer Biomarker(BCR-ABL1 Mbcr, JAK2, CALR, MPL, PML-RARA, NPM1, RUNX1-RUNX1T1, CBFB-MYH11, BCR-ABL1 mbcr), By End-user (National Reference Lab / Specialty Lab, University Hospital / Oncology Center, Community Hospital / IDN (Regional/National))) Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Onco-hematology Molecular Testing Market is valued at US$ 497.67 Mn in 2022, and it is expected to reach US$ 1280.06 Mn by 2031, with a CAGR of 11.2% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1995

Hemato-oncology is a specialized branch of medicine focused on the diagnosis, treatment, and prevention of hematological disorders, including malignancies such as lymphoma and myeloma. The rising incidence of these cancers is expected to drive significant growth in the hemato-oncology market over the forecast period. For instance, according to the American Cancer Society, Non-Hodgkin lymphoma (NHL) is among the most commonly diagnosed cancers in the United States, accounting for approximately 4.0% of all cancer cases.

Molecular diagnostics in oncology play a critical role by analyzing biological molecules within cancer cells to enable accurate detection, classification, and disease monitoring. These diagnostics involve identifying and quantifying specific genetic sequences within DNA, RNA, and associated cellular proteins, typically using blood, saliva, or tissue samples derived from tumors. By providing rapid and comprehensive molecular insights, these tools facilitate the development of personalized and targeted treatment strategies for cancer patients.

Molecular diagnostic technologies are deployed across point-of-care (POC) environments as well as broader clinical testing frameworks to support early cancer detection and ongoing disease management. Additionally, blood banks utilize these technologies to screen samples for infectious agents and pathogens, enhancing transfusion safety and contributing to overall public health initiatives.

List of Prominent Players in the Onco-hematology Molecular Testing Market:
• Asusragen, Inc.
• Bio-Rad Laboratories, Inc.
• ICON plc
• Illumina, Inc.
• Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
• Invivoscribe, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Cepheid

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The global oncology molecular diagnostics market is poised for substantial growth, driven by multiple factors, including the rising prevalence of various cancers, the increasing adoption of precision medicine, heightened demand for preventive healthcare, integration of advanced and automated diagnostic technologies, and supportive reimbursement frameworks.

According to the World Health Organization, approximately 18.0 million new cancer cases were reported globally in 2018, a trend that is expected to further accelerate demand for molecular diagnostics in oncology. However, high costs associated with these diagnostic solutions, budgetary limitations, and the requirement for specialized laboratory infrastructure may pose constraints on market expansion.

Challenges:
The COVID-19 pandemic disrupted the global allocation of hospital resources for oncology care, significantly affecting the management of hematologic malignancies such as lymphoma and multiple myeloma. A study published in Haematological Oncology (October 2022) highlighted the pandemic's impact on patient care across regions, placing additional strain on healthcare systems and potentially affecting clinical outcomes.

Furthermore, research reported in the Journal of Clinical Oncology (September 2022) noted a 22% reduction in new multiple myeloma diagnoses in the United States during the early stages of the pandemic. Despite these challenges, the latter phases of the pandemic witnessed a recovery in demand for cancer diagnostics as healthcare facilities addressed the backlog of cases.

Regional Trends:
North America remains a dominant region in the global hematologic cancer diagnostics market, supported by a high disease burden, an aging population, increased awareness of innovative treatment approaches, and the strong presence of leading industry players. The region's market leadership is reinforced by the growing prevalence of blood cancers, including leukemia, lymphoma, and multiple myeloma. For example, data from the Canadian Cancer Society indicate that in 2021, approximately 6,700 new leukemia cases were diagnosed in Canada-4,000 among men and 2,700 among women-underscoring the sustained demand for advanced diagnostic and therapeutic solutions.

Recent Developments:
• In Mar 2023, Servier and QIAGEN partnered to create a new mIDH1 companion diagnostic test to help Servier's onco-hematology portfolio. This test was used with Servier's tailored treatments for Acute Myeloid Leukaemia (AML) that were on the market and still being researched.
• In Apr 2021, Kartos Therapeutics and Illumina announced a new oncology partnership to create a TP53 companion diagnostic based on NGS. The TSO 500 with peripheral whole blood as a diagnostic sample type was first used in this companion diagnostic for various hematologic purposes.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1995

Segmentation of Onco-hematology Molecular Testing Market-
• Blood Cancer Type
o Chronic Myeloid Leukemia
 Polycythemia Vera
 Essential Thrombocythaemia
 Myelofibrosis
o Myeloproliferative Neoplasms
o Acute Myeloid Leukemia
o Acute Lymphoblastic Leukemia
• Technology
o qPCR
o dPCR
o Next-Generation Sequencing
o Others
• Blood Cancer Biomarker
o BCR-ABL1 Mbcr
o JAK2
o CALR
o MPL
o PML-RARA
o NPM1
o RUNX1-RUNX1T1
o CBFB-MYH11
o BCR-ABL1 mbcr
• End-user
o National Reference Lab / Specialty Lab
o University Hospital / Oncology Center
o Community Hospital / IDN (Regional/National)
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/onco-hematology-molecular-testing-market/1995

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.